Author

Anne Bellon

Observed name: Bellon, Anne

Observed institutions: Scripps Research Institute, Inserm, Hexal (Germany), Debiopharm (Switzerland), Virologie et Immunologie Moléculaires, LFB (France), CSL (Germany)

ORCID: 0009-0006-4723-0550

Observed ORCID: 0009-0006-4723-0550

OpenAlex ID: A5111964426

Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease

2005 · Magdalini Polymenidou, Katharina Stoeck, et al. · The Lancet Neurology · 210

The POM Monoclonals: A Comprehensive Set of Antibodies to Non-Overlapping Prion Protein Epitopes

2008 · Magdalini Polymenidou, Rita Moos, et al. · PLoS ONE · 173

PDF

High Titers of Transmissible Spongiform Encephalopathy Infectivity Associated with Extremely Low Levels of PrPSc in Vivo

2007 · Rona M. Barron, Susan L. Campbell, et al. · Journal of Biological Chemistry · 158

PDF

Toward Molecular Dissection of PrPC-PrPSc Interactions

2007 · Laura Solforosi, Anne Bellon, et al. · Journal of Biological Chemistry · 90

Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal Cultures

2007 · Sabrina Cronier, Vincent Beringue, et al. · Journal of Virology · 74

Probing the Conformation of the Prion Protein within a Single Amyloid Fibril Using a Novel Immunoconformational Assay

2006 · Vera Novitskaya, Natallia Makarava, et al. · Journal of Biological Chemistry · 62

PDF

Differentiation-Dependent Redistribution of Heparan Sulfate in Epithelial Intestinal Caco-2 Cells Leads to Basolateral Entry of Cytomegalovirus

2001 · Audrey Esclatine, Anne Bellon, et al. · Virology · 34

Identifying Key Components of the PrPC-PrPSc Replicative Interface

2008 · Gil C. Abalos, Justin T. Cruite, et al. · Journal of Biological Chemistry · 33

Clinical pharmacology, efficacy and safety study of a triple‐secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency

2019 · Claudia Djambas Khayat, Mohamed El Khorassani, et al. · Journal of Thrombosis and Haemostasis · 31

PDF

Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.

2023 · Hans Gelderblom, Mathilde Jalving, et al. · Journal of Clinical Oncology · 16

Population pharmacokinetics of a triple‐secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age‐ and body weight‐related differences and consequences for dose adjustment in children

2019 · Anne Bellon, Eliane Fuseau, et al. · British Journal of Clinical Pharmacology · 16

PDF

A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency

2017 · Gergely Krivan, Ludmila Chernyshova, et al. · Journal of Clinical Immunology · 13

PDF

A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics

2020 · Anne Bellon, Jessie Wang, et al. · British Journal of Clinical Pharmacology · 12

PDF

Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma

2017 · Caroline Goussen, Steve Simoneau, et al. · BioDrugs · 12

PDF

Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data.

2024 · Kyriakos P. Papadopoulos, Manish Sharma, et al. · Journal of Clinical Oncology · 10

Decontamination of prions in a plasma product manufacturing environment

2013 · Anne Bellon, Emmanuel Comoy, et al. · Transfusion · 8

A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.

2022 · Kyriakos P. Papadopoulos, Manish Sharma, et al. · Journal of Clinical Oncology · 7

Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20,

2011 · Anne Bellon, Alain Sadoun, et al. · Blood · 4

Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.

2025 · Valentina Gambardella, Alejandro Navarro, et al. · Journal of Clinical Oncology · 3

PDF

A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)

2022 · Sanjiv S. Agarwala, Ulrich Nagl, et al. · Current Medical Research and Opinion · 3

PDF

Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim

2021 · Sreekanth Gattu, Jessie Wang, et al. · Clinical Pharmacology in Drug Development · 3

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors

2026 · Kyriakos P. Papadopoulos, Manish R. Sharma, et al. · European Journal of Cancer · 1

Rtid-03. a Phase 1/2 Study of the Wee1 Inhibitor Debio 0123 in Combination With Temozolomide +- Radiotherapy in Adults With Recurrent or Newly Diagnosed Glioblastoma

2023 · Patrick Roth, Kyriakos P Papadopoulos, et al. · Neuro-Oncology · 1

PDF

Debio 0123 (zedoresertib), a selective WEE1 inhibitor, in combination with carboplatin in adult patients with platinum-resistant ovarian cancer: Expansion part of the Debio0123-101 phase 1 study.

2026 · Arjun Oberoi, Antonio Gonzalez Martin, et al. · Journal of Clinical Oncology

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

2025 · Naval Daver, Andrew Sochacki, et al. · Blood

Works count: 33

Citation count: 974

H-index: 12

I10-index: 15